SCHEMBL5155320

SCHEMBL5155320

[C]1CC2CCC=CC2N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL450009 0.71
SCHEMBL10914129 0.64
SCHEMBL8901938 0.62 CHRNB2 (0.30)
SCHEMBL10757117 0.61 EPAS1 (0.32)
SCHEMBL8603606 0.60 EPAS1 (0.34)
SCHEMBL2504646 0.60
SCHEMBL14244062 0.58
SCHEMBL5635555 0.57 SRD5A1 (0.30)
Bicarbonate SCHEMBL11152407 0.57 EGLN1 (0.31)
SCHEMBL56056 0.56

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1654225-A4 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AMGEN INC (US) 2007-11-28 EP claimed
EP-1654225-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS Amgen, Inc. (US) 2006-05-10 EP claimed
US-20050256161-A1 Melanin concentrating hormone receptor antagonists AMGEN INC. 2005-11-17 US claimed
WO-2005019240-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AMGEN, INC. (US) 2005-03-03 WO claimed
CN-115677443-B Method for constructing 1, 4-diketone compound by olefin 1, 2-dicarbonylation 中国科学院理化技术研究所 2024-07-16 CN disclosed
WO-2024140933-A1 CAMPTOTHECIN DERIVATIVE, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD AND USE THEREFOR 长春金赛药业有限责任公司 2024-07-04 WO disclosed
WO-2024140824-A1 PYRIDAZINE NLRP3 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF 长春金赛药业有限责任公司 2024-07-04 WO disclosed
CN-112805062-B Imidazo [1,2-b ] pyridazines as Trk inhibitors 博善人工智能生物科技有限公司 2024-06-04 CN disclosed
CN-118119619-A SIK inhibitor and composition, preparation method and application thereof 上海美悦生物科技发展有限公司 2024-05-31 CN disclosed
CN-118108700-A Complement factor B inhibitor, pharmaceutical composition, preparation method and application thereof 诺华股份有限公司 2024-05-31 CN disclosed
WO-2024104452-A1 MC4R ANTAGONIST COMPOUND, PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL USE THEREOF 长春金赛药业有限责任公司 2024-05-23 WO disclosed
CN-118047744-A Curcumin heterocoumarin photo-diagnosis and treatment agent compound, and preparation method and application thereof 中国科学院理化技术研究所 2024-05-17 CN disclosed
CN-111410661-A Cap-dependent endonuclease inhibitors and uses thereof 周雨恬 2020-07-14 CN disclosed
CN-111417394-A Benzimidazole derivatives and uses thereof 安进公司 2020-07-14 CN disclosed
EP-1654225-A4 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AMGEN INC (US) 2007-11-28 EP disclosed
EP-1654225-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS Amgen, Inc. (US) 2006-05-10 EP disclosed
US-20050256161-A1 Melanin concentrating hormone receptor antagonists AMGEN INC. 2005-11-17 US disclosed
WO-2005019240-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AMGEN, INC. (US) 2005-03-03 WO disclosed
WO-2000066588-A1 DIRECT C-14 OXIDATION OF OPIOIDS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENTOF HEALTH A ND HUMAN SERVICES (US) 2000-11-09 WO disclosed
US-5280034-A Bis-heterocyclic prostaglandin analogs E. R. SQUIBB & SONS, INC. (US) 1994-01-18 US disclosed